Search - tctmd.com

Displaying 481 - 500 of 4147

Sort: Relevancy | Date

News Conference News

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Shelley Wood

November 19, 2020

News Conference News AHA 2020

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Shelley Wood

November 15, 2020

News Conference News AHA 2020

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

Michael O'Riordan

November 14, 2020

News Daily News

PCI at Ambulatory Centers: More Bleeding but No Penalty in Overall Outcomes

Caitlin E. Cox

November 11, 2020

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

L.A. McKeown

November 11, 2020

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

News Daily News

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

Michael O'Riordan

November 03, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2020

Shelley Wood

October 30, 2020

News Daily News

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

Todd Neale

October 29, 2020

News Daily News

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Michael O'Riordan

October 28, 2020

News Industry News

Medtronic Venous Stent Recieves U.S. FDA Approval to Treat Venous Outflow Obstruction

October 26, 2020

News Daily News

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Michael O'Riordan

October 23, 2020

News Conference News TCT 2020

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

Todd Neale

October 22, 2020

News Conference News TCT 2020

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

L.A. McKeown

October 22, 2020

News Conference News TCT 2020

While Rare, Surgical Removal of TAVR Carries Risks: Global EXPLANT-TAVR Registry

L.A. McKeown

October 21, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Industry News

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

October 17, 2020

News Conference News TCT 2020

Fewer Events and Symptoms With iFR-Optimized PCI, Suggests DEFINE-PCI Trial

Michael O'Riordan

October 17, 2020

News Conference News TCT 2020

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

L.A. McKeown

October 17, 2020

News Conference News TCT 2020

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Shelley Wood

October 17, 2020

Advertisement

‘Healing’ Stent Noninferior to Permanent-Polymer Device: PIONEER III

Latest Post-DES Drug Trial Tests Aspirin Monotherapy After 1 Month of DAPT

Clopidogrel Should Remain Antiplatelet of Choice in Elective PCI: ALPHEUS

PCI at Ambulatory Centers: More Bleeding but No Penalty in Overall Outcomes

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Fewer MIs With Prasugrel Than Ticagrelor in STEMI Patients: ISAR-REACT 5

TCTMD’s Top 10 Most Popular Stories for October 2020

Superiority of Ticagrelor Over Clopidogrel in ACS Questioned

Failure to Access Coronaries After TAVR Almost Exclusive to CoreValve Evolut

Medtronic Venous Stent Recieves U.S. FDA Approval to Treat Venous Outflow Obstruction

More Risk of Death—All, Cardiac, and Noncardiac—With PCI Over Surgery: Meta-analysis

Robotic PCI Can Protect Cath Lab Staff From COVID-19, Small Study Suggests

EXAMINATION Surprise: Few Late Event Gaps Between DES and BMS in STEMI

While Rare, Surgical Removal of TAVR Carries Risks: Global EXPLANT-TAVR Registry

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

CeloNova Announces Late-Breaking Evidence from First-Ever Randomized Controlled Trial Evaluating 14-Days DAPT in Complex Patients at High Bleeding Risk Following PCI

Fewer Events and Symptoms With iFR-Optimized PCI, Suggests DEFINE-PCI Trial

OPTIMIZE: Svelte Direct Stenting Device Fails to Match DES

Stent Polymer Face-off Calls Bioresorbable Coatings Into Question

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content